Bayer’s Roundup settlement proposal caps total payouts at $7.25 bn, with individual awards ranging from $10,000 to $165,000 and a payment horizon of up to 21 years. The terms were presented to a St. Louis federal court on 15 Sept 2026, and a final decision is pending.
Settlement terms
The proposal, filed by Bayer’s Monsanto subsidiary, sets a hard ceiling of US$7.25 billion on all payments related to the glyphosate‑based herbicide litigation. Each eligible plaintiff would receive a one‑time award between US$10,000 (minimum) and US$165,000 (maximum), depending on factors such as disease severity, age at diagnosis and product usage. Payments would be spread over a maximum period of 21 years. All figures are drawn from the Handelsblatt report covering the hearing (Handelsblatt).
| Metric | Value | Unit | Period / Basis |
|---|---|---|---|
| Total settlement cap | 7.25 | billion USD | Maximum over the life of the settlement |
| Individual award minimum | 10,000 | USD | Per plaintiff |
| Individual award maximum | 165,000 | USD | Per plaintiff |
| Payment horizon | 21 | years | Maximum duration of payments |
Source: Handelsblatt (https://www.handelsblatt.com/unternehmen/industrie/bayer-monsanto-fordert-von-us-gericht-genehmigung-des-roundup-vergleichs/100252854.html).
Court timeline
The settlement has already received provisional approval. Judge Timothy Boyer granted a preliminary endorsement in March 2026, signalling that the court found the structure of the offer acceptable pending a full hearing. The final hearing took place on 15 Sept 2026 in St. Louis, where Monsanto formally asked the judge to sign off on the $7.25 bn deal. The judge’s ultimate ruling has not yet been issued, leaving the final status of the settlement uncertain.
Impact on claimants
If approved, the agreement would resolve “tens of thousands” of lawsuits alleging that Roundup caused cancer. The capped total of $7.25 bn means that the average payout per plaintiff would be well below the maximum $165,000, especially for cases judged less severe. Because payments can be stretched over two decades, claimants may receive smaller annual amounts, affecting cash‑flow considerations for individuals seeking immediate medical expenses.
The settlement also includes a clause that the company “has no other way” to settle the litigation, as stated by Monsanto in the filing. Critics of the proposal argue that the total sum is insufficient given the number of claimants, while supporters view the deal as the most certain path to compensation without further protracted trials.
Open questions
- Exact number of eligible plaintiffs: the filing does not disclose how many claimants will qualify for the $10k‑$165k range.
- Final judicial decision: Judge Boyer’s pending ruling will determine whether the caps and payment schedule stand.
- Future litigation risk: The settlement caps Bayer’s liability for Roundup‑related claims, but it does not preclude other product‑related lawsuits.
Until the court issues its final order, investors and plaintiffs alike must watch for any adjustments to the settlement structure or additional regulatory scrutiny.